Floatz logo

Eprenetapopt

Bladder Cancer

Aprea TherapeuticsSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

122 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Eprenetapopt is also rated in:

ovarian serous adenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
54 / 100
View asset →
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53Dormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →